Brivaracetam

Generic Name
Brivaracetam
Brand Names
Briviact, Briviact (in Italy: Nubriveo)
Drug Type
Small Molecule
Chemical Formula
C11H20N2O2
CAS Number
357336-20-0
Unique Ingredient Identifier
U863JGG2IA
Background

Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .

Indication

Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.

Associated Conditions
Partial-Onset Seizures
Associated Therapies
-
Clinical Trials
Related News

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2011-04-20
Last Posted Date
2021-08-17
Lead Sponsor
UCB BIOSCIENCES, Inc.
Target Recruit Count
767
Registration Number
NCT01339559
Locations
🇺🇸

064, Port Charlotte, Florida, United States

🇺🇸

011, Dallas, Texas, United States

🇺🇸

778, Columbus, Ohio, United States

and more 181 locations

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

First Posted Date
2010-12-16
Last Posted Date
2022-07-22
Lead Sponsor
UCB Pharma
Target Recruit Count
768
Registration Number
NCT01261325
Locations
🇺🇸

090, Ocala, Florida, United States

🇺🇸

006, Tucson, Arizona, United States

🇺🇸

044, Sarasota, Florida, United States

and more 204 locations

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2008-09-30
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
108
Registration Number
NCT00761774
Locations
🇺🇸

281, Fresno, California, United States

🇺🇸

285, Peoria, Illinois, United States

🇺🇸

245, Sacramento, California, United States

and more 55 locations

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

First Posted Date
2008-08-18
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Target Recruit Count
20
Registration Number
NCT00736931

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2008-06-17
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
62
Registration Number
NCT00699283

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2008-06-17
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
88
Registration Number
NCT00698581

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Placebo
Drug: Brivaracetam
First Posted Date
2007-07-20
Last Posted Date
2018-04-03
Lead Sponsor
UCB Pharma SA
Target Recruit Count
480
Registration Number
NCT00504881

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Phase 3
Completed
Conditions
Epilepsy
Interventions
Other: Placebo
Drug: Brivaracetam
First Posted Date
2007-06-22
Last Posted Date
2022-07-21
Lead Sponsor
UCB Pharma SA
Target Recruit Count
399
Registration Number
NCT00490035
Locations
🇫🇷

52, Montpellier Cedex, France

🇩🇪

71, Ulm, Germany

🇭🇺

94, Budapest, Hungary

and more 73 locations

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

Phase 2
Completed
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2007-01-17
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
100
Registration Number
NCT00422422
Locations
🇺🇸

113, Chesterfield, Missouri, United States

🇲🇽

611, Chihuahua, Mexico

🇧🇪

203, Brussels, Belgium

and more 36 locations

Effect of Brivaracetam in Photosensitive Epileptic Subjects

Phase 2
Completed
Conditions
Epilepsy
First Posted Date
2006-11-20
Last Posted Date
2009-12-01
Lead Sponsor
UCB Pharma
Target Recruit Count
20
Registration Number
NCT00401648
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy